ORKA
NASDAQ HealthcareOruka Therapeutics, Inc. - Common Stock
Biotechnology
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.
�� 市场数据
| 价格 | $55.23 |
|---|---|
| 成交量 | 1,134,801 |
| 市值 | 3.33B |
| RSI（14日） | 29.1 超卖 |
| 200日均线 | $35.63 |
| 50日均线 | $60.65 |
| 52周最高 | $91.00 |
| 52周最低 | $10.77 |
| Forward P/E | -22.43 |
| Price / Book | 5.73 |
🎯 投资策略评分
ORKA 在各投资策略中的评分。分数越高，越符合该策略目标。
🔍 策略解读
最佳匹配： 🐋 Institutional Whale (50/100) — 此策略 大盘、机构级别股票.
评分最低的策略： 🎈 Over-Hyped (7/100). 单一评分不构成买入或卖出信号 — 请结合多种视角综合判断。 了解如何解读这些评分 →
📚 了解更多
在文本中查找 ORKA in your text
粘贴任何文章、记录或帖子 — 工具将提取 ORKA 以及每一个其他隐藏的股票代码。
免责声明：本数据仅供教育和娱乐用途，不构成金融建议。市场数据可能存在延迟。在做出投资决策之前，请始终进行自己的研究。
数据最后更新： 2026-06-02.